EQUILLIUM, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
EQUILLIUM, INC. (EQ) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $4.84 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2024-03-25
- EQUILLIUM, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $4.84M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2022-12-31 | $4.84M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |